When collecting the clinical features (Gleason score, PSA level and tumor stage) and survival data, we excitedly found that high ADSL gene expression might shorten the time of metastasis-free survival (HR = 1.68 (1.12–2.52), P = 0.012) and biochemical recurrence (HR = 1.57 (1.04–2.37), P = 0.003) (Fig. 2a, b). This evidence concerns the gene ADSL and neoplasm.